We have screened two families for constitutionalTP53 mutations, one familywith Li-Fraumeni syndrome and the other with features of this syndrome. We report a germline mutation in exon 7 of the TP53 gene in the family with "Li-Fraumenilike" syndrome. The mutation occurred at codon 245 and causes a Gly-Ser amino acid change. It was inherited by both affected and unaffected subjects. Malignant tumours from all members of this family showed strong positive nuclear immunohistochemical staining with antibodies CM-1 and DOI, directed against TP53. In contrast, no constitutional TP53 mutations were found in a "classic" LiFraumeni family. In this family positive staining was seen in both malignant and normal tissues. These results support previous findings that variants ofthe Li-Fraumeni syndrome exist since not all LFS families carry TP53 germline mutations. Secondly, immunohistochemical positivity is not synonymous with an underlying mutation and is therefore inadequate as an exclusive diagnostic marker. (JMed Genet 1995;32:186-190 
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Discussion
Germline TP53 mutations have been identified as being the genetic basis of the Li-Fraumeni syndrome (LFS).24 We report the presence of TP53 mutation in one "Li-Fraumeni-like" family (family 2), but not in a family (family 1) satisfying the original criteria of Li and Fraumeni.' The mutation found in family 2 was in exon 7 of the gene at position 1 in codon 245 and caused a Gly-Ser amino acid change. The same mutation was found in other affected family members and also in an unaffected person indicating that the mutation has been transmitted through the germline. This subject is young and still has a substantial risk of developing cancer. In contrast, in family 1, no mutation was found in this region or at any other position tested within the TP53 gene. Since this study was finished further analysis of the p53 gene from family 1 has been carried out and all the exons have been analysed. No mutations were identified in exons 1-4 which were not analysed in this study (R A Eeles, personal communication). This and other studies suggest that not all LFS families have detectable germline mutations. For example, Santibanez-Koref et a17 have reported germline mutations in only two out ofeight LFS families.
Originally in that study only the conserved region in exon 7 was sequenced; however a further three germline mutations have since been found by these authors in exons 4, 5, and 6.'
The presence of positive p53 staining in malignant tissues is often indicative of an abnormally stablised p53 protein. Initially this stablisation was taken as good evidence of a mutation within the TP53 gene. However, recent reports""9 have shown that p53 immunopositivity is not necessarily synonymous with a mutation within the gene. In the present studywe have performed immunohistochemical staining on available formalin fixed paraffin embedded tissue from our two familites. Both exhibited similar staining patterns in the malignant cells. Family 1, however, also showed positive staining in normal epithelial and mesenchymal cells. No constitutional mutations were found in this family.
We have described previously a similar finding in a cancer family patient where abnormal expression of wild type p53 protein was detected in normal cells, particularly in skin surrounding the tumour. Despite extensive sequencing no mutations were identified and biochemical analysis of the p53 protein extracted from cultured normal fibroblasts indicated that the protein was wild type. ' pattern is similar to our own the degree of staining is not nearly as extensive as that observed in our families. The patient described by Eeles et al'9 was found to have a mutation in exon 8 of the TP53 gene whereas members from our family 1 and our previously described patient'6 did not show any germline TP53 mutations. In contrast, in family 2, we have found a germline mutation in six members of a family classified as "Li- Low levels of mutant and wild type p53 protein were detected in NSF cells from the family members carrying the germline mutation. In our study, those family members who carried the TP53 codon 245 mutation showed no evidence of strong staining of normal cells as detected immunohistochemically by the antibodies CM-1 and DO1, although some weak staining of normal tissue was seen in the proband. These observations perhaps suggest different functional implications of the types of TP53 mutations inherited. However, further cases need to be identified and analysed in order to address this question. It is reasonable to assume that the alteration of the TP53 gene leading to detectable levels of p53 protein in family 2 is because of the mutation at codon 245. A number of possibilities exist that could account for the positive immunostaining observed in family 1, including a mutation elsewhere in the TP53 gene or a mutation in a regulator element. When the mechanism is fully elucidated it should then be possible to explain and perhaps to correlate the different types of staining patterns observed. However, irrespective of the underlying causes, it is obvious that immunostaining is not a satisfactory predictive marker of all mutations although it does show alterations in the stability of p53 protein which may reflect altered function.
These findings have important implications for predictive testing. It is clear that immunohistochemical staining of tumours is sufficient to identify germline mutations of TP53. Also the clinical definition used to identify Li-Fraumeni families is not sufficient to identify all patients with TP53 mutations.
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